Pharmaceutical Ingredient Loteprednol Etabonate CAS 82034-46-6

• Toz: Evet
• Özelleştirilmiş: Özelleştirilmemiş
• Sertifika: GMP, HSE, ISO 9001, USP, BP
• Uygun olduğu: Yaşlılar, Çocuklar, Yetişkin
• Ifade: Katı
• Saflık: %99
• Hayır. Modeli.: Pharmaceutical Grade
• yüce etnol etabonat: usp
• Taşıma Paketi: Drum
• Teknik Özelikler: 25kg
• Ticari Marka: flying deer
• Menşei: Çin
• Üretim Kapasitesi: 2300 Tons Yearly

Ürün Açıklaması

Pharmaceutical Ingredient Loteprednol Etabonate CAS 82034-46-6
 

Product Name:Loteprednol etabonate CAS:82034-46-6 MF:C24H31ClO7 MW:466.95 EINECS:200-010-0 Mol File:82034-46-6.mol

Melting point:220.5-223.5 Boiling point:600.1±55.0 °C(Predicted) Density 1.31±0.1 g/cm3(Predicted) storage temp. -20°C Freezer solubility DMSO: soluble5mg/mL, clear (warmed) pka14.06±0.70(Predicted) form powder color white to beige Water Solubility <1mg/L(23 ºC)

 

Loteprednol (as Loteprednol Etabonate) is a topical anti-inflammatory corticosteroid. Loteprednol etabonate (LE) has a 17α-chloromethyl ester, in lieu of a ketone group, and a 17β-etabonate group. LE is highly lipophilic and binds with high affinity to the glucocorticoid receptor. Any unbound LE is metabolized to inactive metabolites. Loteprednol etabonate is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitis. It is used in ophthalmic ointment for the treatment of post-operative inflammation and pain following ocular surgery. As a nasal spray, it is used for the treatment and management of seasonal allergic rhinitis.

Function :

Common adverse effects include foreign body sensation in the eye, dry eye and epiphora (overflow of tears), chemosis (swelling of the conjunctiva), headache, and itching. Increased intraocular pressure (IOP), a side effect typical of corticosteroids, occurs in about 2% of patients (compared to 7% under acetate, an older anti-inflammatory agent which is prescribed after eye surgery, and 0.5% under placebo). Loteprednol is also far less likely to cause elevated IOP compared to

Application :Loteprednol etabonate is used for the treatment of inflammation of the eye due to allergies,as well as chronic forms of keratitis, vernal keratoconjunctivitis, pingueculitis, and episcleritis.